Top Line: Does cannabis improve nausea control for patients receiving chemotherapy?
The Study: Even though “medical” cannabis is a hot topic, there’s very limited data to guide the use of cannabis in oncology. In this randomized, placebo-controlled phase II/III trial, 147 patients who had refractory nausea and vomiting from systemic therapy regimens with moderate to high emetogenic risk were randomized to receive standard antiemetic therapy (steroids, 5-HT3 antagonist, NK-1 inhibitor, and olanzapine) with or without oral cannabis extract. The cannabis treatment consisted of capsules containing 2.5mg tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). This was taken 3 times per day starting the day before chemo and ending on day 5, but patients could self-titrate up to a dose of 4 capsules 3 times per day. The complete response rate was significantly higher in the THC:CBD arm (24% v 8%), and those patients had less vomiting and a lower requirement of rescue treatment for nausea. However, patients in the THC:CBD arm reported more adverse effects including sedation (18% v 7%) and dizziness (10% v 0%).
TBL: In this randomized trial, THC:CBD showed efficacy in treating patients with refractory chemotherapy induced nausea and vomiting. | Grimison, J Clin Oncol 2024
The Study: Even though “medical” cannabis is a hot topic, there’s very limited data to guide the use of cannabis in oncology. In this randomized, placebo-controlled phase II/III trial, 147 patients who had refractory nausea and vomiting from systemic therapy regimens with moderate to high emetogenic risk were randomized to receive standard antiemetic therapy (steroids, 5-HT3 antagonist, NK-1 inhibitor, and olanzapine) with or without oral cannabis extract. The cannabis treatment consisted of capsules containing 2.5mg tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). This was taken 3 times per day starting the day before chemo and ending on day 5, but patients could self-titrate up to a dose of 4 capsules 3 times per day. The complete response rate was significantly higher in the THC:CBD arm (24% v 8%), and those patients had less vomiting and a lower requirement of rescue treatment for nausea. However, patients in the THC:CBD arm reported more adverse effects including sedation (18% v 7%) and dizziness (10% v 0%).
TBL: In this randomized trial, THC:CBD showed efficacy in treating patients with refractory chemotherapy induced nausea and vomiting. | Grimison, J Clin Oncol 2024

